Dergiler / Turkish Journal of Internal Medicine / 2021 / Cilt: 3 - Sayı: 2

Results and adverse effect evaluations in localized prostate cancer patients undergoing intensity modulated radiotherapy with tomotherapy

Sayfa
73–79
Yayın Tarihi
2021-04-29
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Increased toxicity was not observed in the cases with lymph node irradiation despite the increased radiotherapy field.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim To assess the dosimetric results and early and late adverse effects of radiotherapy with tomotherapy in localized prostate cancer patients.
📊
Temel Bulgular & Veri:Materials and Methods Treatment results and early and late adverse effects in 60 patients who had undergone curative radiotherapy due to prostate cancer and who had been followed-up for at least 6 months in the post-treatment process were assessed retrospectively. 28 of the patients were in the low-intermediate risk group, whereas 32 of them were in the high-risk group. 74 Gy radiotherapy was delivered to the prostate with simultaneous integrated boost strategy, 60 Gy to seminal vesicles and 52 Gy to pelvic lymph nodes of the cases.
💡
Sonuç & Katkı:Increased toxicity was not observed in the cases with lymph node irradiation despite the increased radiotherapy field.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Prostate cancer · intensity modulated radiotherapy · acute-late toxicity

Abstract

Aim To assess the dosimetric results and early and late adverse effects of radiotherapy with tomotherapy in localized prostate cancer patients. Materials and Methods Treatment results and early and late adverse effects in 60 patients who had undergone curative radiotherapy due to prostate cancer and who had been followed-up for at least 6 months in the post-treatment process were assessed retrospectively. 28 of the patients were in the low-intermediate risk group, whereas 32 of them were in the high-risk group. 74 Gy radiotherapy was delivered to the prostate with simultaneous integrated boost strategy, 60 Gy to seminal vesicles and 52 Gy to pelvic lymph nodes of the cases. Patients with at least 6 months of post-treatment follow-up were assessed in terms of early and late adverse effects. Results Twenty patients had grade 1 and two patients had grade 2 acute genitourinary toxicity, whereas 15 patients had grade 1 and 4 patients had grade 2 acute gastrointestinal toxicity. Twelve patients had grade 1 and 3 patients had grade 2 late genitourinary toxicity, 6 patients had grade 1 and two other patients had grade 2 and grade 3 late gastrointestinal toxicity. Biochemical recurrence developed in four patients. One of the patients with recurrence died in the 14th month of recurrence due to organ metastasis. Conclusions Image-guided dose-escalated radiotherapy with IMRT technique is a reliable method in prostate cancer treatment. Increased toxicity was not observed in the cases with lymph node irradiation despite the increased radiotherapy field.

🔖

Bu Makaleye Atıf Yap

ÖZTÜRK, G. A., OZTURK, M. (2021). Results and adverse effect evaluations in localized prostate cancer patients undergoing intensity modulated radiotherapy with tomotherapy. Turkish Journal of Internal Medicine, Cilt: 3 - Sayı: 2, 73–79. https://ajindex.com/articles/809048

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Rawla P. Epidemiology of prostate cancer. World journal of oncology 2019; 10(2), 63. Mangar SA, Huddart RA, Parker CC, Dearnaley DP, Khoo VS, Horwich A. Technological advances in radiotherapy for the treatment of localised prostate cancer. European Journal of Cancer 2005; 41(6), 908-21.
  2. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Zattoni F. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European urology 2011; 59(1), 61-71.
  3. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Collette L. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. The lancet oncology 2010; 11(11), 1066-73.
  4. Hong TS, Ritter MA, Tome WA, Harari PM. Intensity-modulated radiation therapy: emerging cancer treatment technology. British journal of cancer 2005; 92(10), 1819-24.
  5. Yeoh EE, Botten R, Russo A, McGowan R, Fraser R, Roos D, Sun WM. Chronic effects of therapeutic irradiation for localized prostatic carcinoma on anorectal function. International Journal of Radiation Oncology* Biology* Physics 2000; 47(4), 915-24.
  6. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, Rosen I. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. International Journal of Radiation Oncology* Biology* Physics 2002; 53(5), 1097-1105.
  7. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Pollack A. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology* Biology* Physics 2008; 70(1), 67-74.
  8. Pollack A, Zagars GK, Smith LG, Lee JJ, Von Eschenbach AC, Antolak JA, Rosen I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology 2000; 18(23), 3904-11.
  9. Peeters ST, Heemsbergen WD, Koper PC, Van Putten WL, Slot A, Dielwart MF, Lebesque JV. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24(13), 1990-96.
  10. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. J